Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: A novel approach

Journal of Asthma

Volumn 46, Issue 5, 2009, Pages 445-447

  Randhawa, Inderpal ^a   Chin, Terry ^a   Nussbaum, Eliezer ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allergic bronchopulmonary aspergillosis; Omalizumab

Indexed keywords

CEFEPIME; CORTICOSTEROID; DORNASE ALFA; FLUTICASONE; GLUCOSE; INSULIN; ITRACONAZOLE; LANSOPRAZOLE; MULTIVITAMIN; OMALIZUMAB; PANCREAS ENZYME; PREDNISONE; SALBUTAMOL; TOBRAMYCIN; ANTIALLERGIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADOLESCENT; AFRICAN AMERICAN; ARTICLE; ASTHMA; BRONCHOPULMONARY ASPERGILLOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LUNG FUNCTION TEST; MALE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SIDE EFFECT; THORAX RADIOGRAPHY; CHEMICALLY INDUCED DISORDER; LUNG ASPERGILLOSIS;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CYSTIC FIBROSIS; DIABETES MELLITUS; GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA; MALE;

EID: 67650324692     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900902849871     Document Type: Article

References (20)

1. Stevens DA, Moss RB, Kurup VP, and participants in the Cystic Fibrosis Foundation Consensus Conference, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37:S225-264.
2. El Dahr JM, Fink R, Selden R, Arruda LK, Platts-Mills TA, Heymann PW. Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150:1513-1518.
3. Leser C, Kauffman HF, Virchow C Sr, Menz G. Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1992; 90:589-599.
4. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.
5. Paquot N, Schneiter P, Jequier E, Tappy L. Effects of glucocorticoids and sympathomimetic agents on basal and insulin-stimulated glucose metabolism. Clin Physiol 1995; 15:231-240.
6. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. de Almeida MB, Bussamra MH, Rodrigues JC. Paediatr Respir Rev 2006; 7:67-72.
7. van der Ent CK; Hoekstra H; Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62:276-277.
8. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43:607-610.
9. Localization of IgE to lung germinal lymphoid follicles in a patient with allergic bronchopulmonary aspergillosis. Slavin RG, Gleich GJ, Hutcheson PS, Kephart GM, Knutsen AP, Tsai CC. J Allergy Clin Immunol 1992; 90:1006-1008.
10. A pathologic study of allergic bronchopulmonary aspergillosis. Slavin RG, Bedrossian CW, Hutcheson PS, Pittman S, Salinas-Madrigal L, Tsai CC, Gleich GJ. J Allergy Clin Immunol 1988; 81:718-725.
11. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Patterson R, Greenberger PA, Radin RC, Roberts M. Ann Intern Med 1982; 96: 286-291.
12. Allergic bronchopulmonary aspergillosis. Greenberger PA. J Allergy Clin Immunol 2002; 110:685-692.
13. Wark P. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment. Respir Med 2004; 98:915- 923.
14. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. In: Report of a WHO consultation. Geneva: World Health Organization, 1999:1-59.
15. Mathis AS, Liu MT, Adamson RT, Nambi SS, Patel AM. Retrospective analysis of early steroid-induced adverse reactions in kidney and kidney-pancreas transplant recipients. Transplant Proc 2007; 39:199- 201.
16. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 2002; 19:221-226.
17. O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes. ISPAD Clinical Practice Consensus. Pediatr Diabetes 2008; 28:338-44.
18. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43:1249-1251.
19. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (oma-lizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632- 638.
20. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19:491-498.